205 related articles for article (PubMed ID: 30186169)
1. Ileal Bile Acid Transporter Inhibition for the Treatment of Chronic Constipation, Cholestatic Pruritus, and NASH.
Al-Dury S; Marschall HU
Front Pharmacol; 2018; 9():931. PubMed ID: 30186169
[TBL] [Abstract][Full Text] [Related]
2. Systemic ASBT inactivation protects against liver damage in obstructive cholestasis in mice.
Kunst RF; de Waart DR; Wolters F; Duijst S; Vogels EW; Bolt I; Verheij J; Beuers U; Oude Elferink RPJ; van de Graaf SFJ
JHEP Rep; 2022 Nov; 4(11):100573. PubMed ID: 36160754
[TBL] [Abstract][Full Text] [Related]
3. [The inhibitors of the apical sodium-dependent bile acid transporter (ASBT) as promising drugs].
Saveleva EE; Tyutrina ES; Nakanishi T; Tamai I; Salmina AB
Biomed Khim; 2020 May; 66(3):185-195. PubMed ID: 32588824
[TBL] [Abstract][Full Text] [Related]
4. Potential of ileal bile acid transporter inhibition as a therapeutic target in Alagille syndrome and progressive familial intrahepatic cholestasis.
Kamath BM; Stein P; Houwen RHJ; Verkade HJ
Liver Int; 2020 Aug; 40(8):1812-1822. PubMed ID: 32492754
[TBL] [Abstract][Full Text] [Related]
5. BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial.
Hegade VS; Kendrick SF; Dobbins RL; Miller SR; Richards D; Storey J; Dukes G; Gilchrist K; Vallow S; Alexander GJ; Corrigan M; Hirschfield GM; Jones DE
BMC Gastroenterol; 2016 Jul; 16(1):71. PubMed ID: 27431238
[TBL] [Abstract][Full Text] [Related]
6. Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders.
Karpen SJ; Kelly D; Mack C; Stein P
Hepatol Int; 2020 Sep; 14(5):677-689. PubMed ID: 32653991
[TBL] [Abstract][Full Text] [Related]
7. Elobixibat, the first-in-class Ileal Bile Acid Transporter inhibitor, for the treatment of Chronic Idiopathic Constipation.
Miner PB
Expert Opin Pharmacother; 2018 Aug; 19(12):1381-1388. PubMed ID: 30129377
[TBL] [Abstract][Full Text] [Related]
8. Combined inhibition of bile salt synthesis and intestinal uptake reduces cholestatic liver damage and colonic bile salts in mice.
Kunst RF; Bolt I; van Dasselaar RDJ; Nijmeijer BA; Beuers U; Oude Elferink RPJ; van de Graaf SFJ
JHEP Rep; 2024 Jan; 6(1):100917. PubMed ID: 38074508
[TBL] [Abstract][Full Text] [Related]
9. Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis.
Al-Dury S; Wahlström A; Wahlin S; Langedijk J; Elferink RO; Ståhlman M; Marschall HU
Sci Rep; 2018 Apr; 8(1):6658. PubMed ID: 29704003
[TBL] [Abstract][Full Text] [Related]
10. Metabolic consequences of ileal interruption of the enterohepatic circulation of bile acids.
van de Peppel IP; Verkade HJ; Jonker JW
Am J Physiol Gastrointest Liver Physiol; 2020 Nov; 319(5):G619-G625. PubMed ID: 32938201
[TBL] [Abstract][Full Text] [Related]
11. Randomised clinical trial: The ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation--a double-blind study.
Simrén M; Bajor A; Gillberg PG; Rudling M; Abrahamsson H
Aliment Pharmacol Ther; 2011 Jul; 34(1):41-50. PubMed ID: 21545606
[TBL] [Abstract][Full Text] [Related]
12. Adaptive regulation of the ileal apical sodium dependent bile acid transporter (ASBT) in patients with obstructive cholestasis.
Hruz P; Zimmermann C; Gutmann H; Degen L; Beuers U; Terracciano L; Drewe J; Beglinger C
Gut; 2006 Mar; 55(3):395-402. PubMed ID: 16150853
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of ileal bile acid absorption in bile-duct-ligated rats.
Sauer P; Stiehl A; Fitscher BA; Riedel HD; Benz C; Klöters-Plachky P; Stengelin S; Stremmel W; Kramer W
J Hepatol; 2000 Jul; 33(1):2-8. PubMed ID: 10905579
[TBL] [Abstract][Full Text] [Related]
14. [Hypolipidemic drugs--ileal Na+/bile acid cotransporter inhibitors (S-8921 etc)].
Ichihashi T
Nihon Rinsho; 2002 Jan; 60(1):130-6. PubMed ID: 11808323
[TBL] [Abstract][Full Text] [Related]
15. Odevixibat: a promising new treatment for progressive familial intrahepatic cholestasis.
Bedoyan SM; Lovell OT; Horslen SP; Squires JE
Expert Opin Pharmacother; 2022 Nov; 23(16):1771-1779. PubMed ID: 36278881
[TBL] [Abstract][Full Text] [Related]
16. An important intestinal transporter that regulates the enterohepatic circulation of bile acids and cholesterol homeostasis: The apical sodium-dependent bile acid transporter (SLC10A2/ASBT).
Xiao L; Pan G
Clin Res Hepatol Gastroenterol; 2017 Oct; 41(5):509-515. PubMed ID: 28336180
[TBL] [Abstract][Full Text] [Related]
17. Cholestatic Itch: Our Current Understanding of Pathophysiology and Treatments.
Vander Does A; Levy C; Yosipovitch G
Am J Clin Dermatol; 2022 Sep; 23(5):647-659. PubMed ID: 35900649
[TBL] [Abstract][Full Text] [Related]
18. Odevixibat: an investigational inhibitor of the ileal bile acid transporter (IBAT) for the treatment of biliary atresia.
Laue T; Baumann U
Expert Opin Investig Drugs; 2022 Nov; 31(11):1143-1150. PubMed ID: 36440482
[TBL] [Abstract][Full Text] [Related]
19. Elobixibat for the treatment of constipation.
Chedid V; Vijayvargiya P; Camilleri M
Expert Rev Gastroenterol Hepatol; 2018 Oct; 12(10):951-960. PubMed ID: 30204504
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial.
Tiessen RG; Kennedy CA; Keller BT; Levin N; Acevedo L; Gedulin B; van Vliet AA; Dorenbaum A; Palmer M
BMC Gastroenterol; 2018 Jan; 18(1):3. PubMed ID: 29304731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
